Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

Kenji Fukuno, Takeshi Hara, Hisashi Tsurumi, Yuhei Shibata, Ryoko Mabuchi, Nobuhiko Nakamura, Junichi Kitagawa, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito, Hisataka Moriwaki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.

Original languageEnglish
Pages (from-to)1398-1405
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number5
DOIs
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Acute Myeloid Leukemia
Cytogenetics
Messenger RNA
Polymerase Chain Reaction
Reverse Transcription
Bone Marrow
Essential Amino Acids
Tryptophan
Survival Rate

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Fukuno, Kenji ; Hara, Takeshi ; Tsurumi, Hisashi ; Shibata, Yuhei ; Mabuchi, Ryoko ; Nakamura, Nobuhiko ; Kitagawa, Junichi ; Shimizu, Masahito ; Ito, Hiroyasu ; Saito, Kuniaki ; Moriwaki, Hisataka. / Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 5. pp. 1398-1405.
@article{4f10c73ea4534975a854a4041ca8593b,
title = "Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics",
abstract = "The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39{\%} and 74{\%}, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16{\%} and 70{\%}, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.",
author = "Kenji Fukuno and Takeshi Hara and Hisashi Tsurumi and Yuhei Shibata and Ryoko Mabuchi and Nobuhiko Nakamura and Junichi Kitagawa and Masahito Shimizu and Hiroyasu Ito and Kuniaki Saito and Hisataka Moriwaki",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.953150",
language = "English",
volume = "56",
pages = "1398--1405",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. / Fukuno, Kenji; Hara, Takeshi; Tsurumi, Hisashi; Shibata, Yuhei; Mabuchi, Ryoko; Nakamura, Nobuhiko; Kitagawa, Junichi; Shimizu, Masahito; Ito, Hiroyasu; Saito, Kuniaki; Moriwaki, Hisataka.

In: Leukemia and Lymphoma, Vol. 56, No. 5, 01.01.2015, p. 1398-1405.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics

AU - Fukuno, Kenji

AU - Hara, Takeshi

AU - Tsurumi, Hisashi

AU - Shibata, Yuhei

AU - Mabuchi, Ryoko

AU - Nakamura, Nobuhiko

AU - Kitagawa, Junichi

AU - Shimizu, Masahito

AU - Ito, Hiroyasu

AU - Saito, Kuniaki

AU - Moriwaki, Hisataka

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.

AB - The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid l-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.

UR - http://www.scopus.com/inward/record.url?scp=84932080600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932080600&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.953150

DO - 10.3109/10428194.2014.953150

M3 - Article

C2 - 25248875

AN - SCOPUS:84932080600

VL - 56

SP - 1398

EP - 1405

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -